Laboratory and clinical studies on amikacin
Wang, Q.N.; Du, J.Z.; Liu, Y.H.; Jiang, Y.F.; Sheng, J.Q.; Qiu, Z.D.; Luo, M.Y.
Chinese Medical Journal 98(11): 807-816
1985
ISSN/ISBN: 0366-6999 PMID: 3938711 Document Number: 261693
Amikacin and other aminoglycoside antibiotics were tested for in vitro antibacterial activity against 480 strains of common pathogens, including Staphylococcus aureus. Escherichia coli, Shigella, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter, Proteus etc. The results indicated that home made amikacin was equal in potency to the Japanese made product. The in vitro antibacterial activity of amikacin was markedly superior to that of kanamycin, gentamycin, tobramycin, and streptomycin. Amikacin was active against organisms resistant to gentamicin, tobramycin and kanamycin. Clinical pharmacological studies were performed on 12 cases with normal renal functions. The peak level was 24.75 .mu.g/ml one hour after intramuscular injection of 400 mg amikacin. The biological half life was 2.39-2.48 hours. Thirty-one cases of infections caused by Gram negative rods and S. aureus were treated. 87.1% were considered effective. Renal and oto-toxicity was minimal. It is concluded that amikacin is a broad-spectrum, high potency aminoglycoside antibiotic, and is especially suitable for the treatment of severe Gram negative infections and those infections that were caused by gentamicin-tobramycin resistant Gram negative rods.